Open Calls for Input and Feedback


Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.

At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.

Draft Recommendations

Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor)

Therapeutic Area: Cystic fibrosis, F508del CFTR mutation, 6 years and older
Draft recommendations posted for stakeholder feedback: May 19, 2022
End of feedback period: June 3, 2022
Draft Recommendation

Submit Feedback

 

Spinraza (nusinersen)

Therapeutic Area: Spinal Muscular Atrophy
Draft recommendations posted for stakeholder feedback: May 19, 2022
End of feedback period: June 3, 2022
Draft Recommendation

Submit Feedback

 

Firdapse (amifampridine phosphate)

Therapeutic Area: Lambert-Eaton Myasthenic Syndrome, adults
Draft recommendations posted for stakeholder feedback: May 19, 2022
End of feedback period: June 3, 2022
Draft Recommendation

Submit Feedback

 

Vyndaqel (tafamidis)

Therapeutic Area: Transthyretin-mediated amyloidosis
Draft recommendations posted for stakeholder feedback: May 19, 2022
End of feedback period: June 3, 2022
Draft Recommendation

Submit Feedback

 

HyQvia (immune globulin human and recombinant human hyaluronidase)

Therapeutic Area: Humoral immunodeficiency
Draft recommendations posted for stakeholder feedback: May 19, 2022
End of feedback period: June 3, 2022
Draft Recommendation

Submit Feedback

 

Open Calls for Patient and Clinician Input

Therapeutic Area
Therapeutic Area: Triple-negative breast cancer
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Metastatic castration-sensitive prostate cancer
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Large B-cell lymphoma
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Migraine
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Transfusional iron overload
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Atypical hemolytic uremic syndrome
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Diabetic macular edema
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Acquired thrombotic thrombocytopenic purpura (aTTP)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Chronic kidney disease
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: recurrent, or metastatic cervical cancer
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed: